Work

Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection

Year: 2026

Type: article

Abstract: The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is < 8%. The best therapeutic option for PDAC is tumor resection. However, most patients experience recurrence within 2 years after surgery[1][1]. Postoperative monitoring includes CT imaging and determining CA19-9

Source: Cancer Biology and Medicine

DOI: 10.20892/j.issn.2095-3941.2025.0495

Authors: Fawaz N. Al-Shaheri, Teresa Colbatzky, Andrea S. Bauer, Chaoyang Zhang, Mohamed S. S. Alhamdani, Henning Boekhoff, Liang Xu, Lucas Sperling, Miriam Schenk, Christin Tjaden, Markus W. Büchler, Thilo Hackert, Natalia A. Giese, Jörg D. Hoheisel, Ulrike Heger

Institutions: German Cancer Research Center, Heidelberg University, University Hospital Heidelberg

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,500

Funders: Deutscher Akademischer Austauschdienst, Bundesministerium für Bildung und Forschung, China Scholarship Council

Award: TRANSCAN III - Verbund: Biomarker zur Detektion von Tumorrezidiven bei Pankreaskarzinompatienten (Bio-PaC)

OpenAlex ID: W7129650168

FWCI:

Cites:

Cited by:

Related to: